Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03924856
Other study ID # 3475-866
Secondary ID MK-3475-866KEYNO
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date June 13, 2019
Est. completion date June 15, 2025

Study information

Verified date October 2023
Source Merck Sharp & Dohme LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 907
Est. completion date June 15, 2025
Est. primary completion date June 15, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Have a histologically confirmed diagnosis of urothelial carcinoma (UC) / muscle invasive bladder cancer (MIBC) (T2-T4aN0M0 or T1-T4aN1M0) with predominant (=50%) urothelial histology. - Have clinically non-metastatic bladder cancer (N=1 M0) determined by imaging (computed tomography (CT) or magnetic resonance imaging (MRI)) of the chest/abdomen/pelvis. - Be deemed eligible for Radical Cystectomy (RC) + Pelvic Lymph Node Dissection (PLND). - Have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. - Have adequate organ function. - Male and female participants are eligible to participate if they agree to the contraception use as per study protocol. Exclusion Criteria: - Has a known additional malignancy that is progressing or has required active anti-cancer treatment =3 years of study randomization with certain exceptions. - Has received any prior systemic treatment for MIBC or non-invasive muscle bladder cancer (NMIBC - prior treatment for NMIBC with intravesical BCG/chemotherapy is permitted) or prior therapy with an anti- programmed cell death 1 (PD-1), anti-programmed cell death ligand 1/ ligand 2 (PD-L1/L2), or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). - Has =N2 disease or metastatic disease (M1) as identified by imaging. - Is cisplatin-ineligible, as defined by meeting any one of the cisplatin ineligibility criteria as per protocol. - Has received prior systemic anticancer therapy including investigational agents within 3 years of randomization or any radiotherapy to the bladder. - Has undergone partial cystectomy of the bladder to remove any NMIBC or MIBC. - Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention. - Has a diagnosis of immunodeficiency or has a known history of human immunodeficiency virus (HIV) infection, Hepatitis B infection or known active Hepatitis C infection. - Has a known psychiatric or substance abuse disorder. - Has had an allogenic tissue/solid organ transplant.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pembrolizumab
Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
Gemcitabine
Gemcitabine 1000 mg/m^2, IV infusion on Days 1 and 8 of each 21-day cycle
Cisplatin
Cisplatin 70 mg/m^2, IV infusion on Day 1 of each 21-day cycle
Procedure:
Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
Drug:
Placebo
Placebo to pembrolizumab by IV infusion, given on Day 1 of each 21-day cycle

Locations

Country Name City State
Australia Eastern Health ( Site 1255) Box Hill Victoria
Australia Cairns Base Hospital ( Site 1257) Cairns Queensland
Australia Peninsula Health Frankston Hospital ( Site 1258) Frankston Victoria
Australia Mid North Coast Cancer Institute ( Site 1256) Port Macquarie New South Wales
Australia Southside Cancer Care Centre ( Site 1252) Sydney New South Wales
Belgium O.L.V. Ziekenhuis Aalst ( Site 0356) Aalst Oost-Vlaanderen
Belgium UZ Brussel ( Site 0358) Brussels Bruxelles-Capitale, Region De
Belgium AZ Maria Middelares Gent ( Site 0353) Gent Oost-Vlaanderen
Belgium Jessa Ziekenhuis ( Site 0360) Hasselt Limburg
Belgium CHU UCL Namur Site de Godinne ( Site 0354) Yvoir Namur
Canada Tom Baker Cancer Centre ( Site 0100) Calgary Alberta
Canada Nova Scotia Health Authority ( Site 0109) Halifax Nova Scotia
Canada Kingston Health Sciences Centre ( Site 0103) Kingston Ontario
Canada CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0105) Montreal Quebec
Canada Lakeridge Health ( Site 0104) Oshawa Ontario
Canada Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0 Quebec City Quebec
Canada Princess Margaret Cancer Centre ( Site 0107) Toronto Ontario
Canada Sunnybrook Research Institute ( Site 0110) Toronto Ontario
Denmark Herlev og Gentofte Hospital. ( Site 0402) Herlev Hovedstaden
Denmark Rigshospitalet University Hospital ( Site 0401) Kobenhavn Hovedstaden
Denmark Odense Universitetshospital ( Site 0403) Odense Syddanmark
France Institut de Cancerologie de l Ouest Site Paul Papin ( Site 0453) Angers Maine-et-Loire
France Institut Sainte Catherine ( Site 0454) Avignon Vaucluse
France CHU de Bordeaux- Hopital Saint Andre ( Site 0456) Bordeaux Aquitaine
France Centre Francois Baclesse ( Site 0459) Caen Calvados
France Centre Jean Perrin ( Site 0460) Clermont-Ferrand Puy-de-Dome
France Clinique Victor Hugo ( Site 0463) Le Mans Sarthe
France Centre Leon Berard ( Site 0465) Lyon Auvergne
France Hopital Robert Schuman ( Site 0452) Metz Moselle
France CHU de Montpellier - Hopital Saint-Eloi ( Site 0469) Montpellier Languedoc-Roussillon
France Centre Armoricain de Radiotherapie Imagerie medicale et Oncologie ( Site 0457) Plerin Cotes-d Armor
France CHU de Rouen ( Site 0493) Rouen Seine-Maritime
France Hopital Foch ( Site 0483) Suresnes Hauts-de-Seine
Germany Charite Universitaetsmedizin Berlin ( Site 0515) Berlin
Germany Vivantes Klinikum am Urban ( Site 0522) Berlin
Germany Universitaetsklinikum Carl Gustav Carus ( Site 0519) Dresden Sachsen
Germany Universitaetsklinikum Erlangen ( Site 0505) Erlangen Bayern
Germany Universitaetsklinikum Schleswig-Holstein-Campus Lubeck ( Site 0512) Luebeck Schleswig-Holstein
Germany Universitaetsklinikum Magdeburg A.o.R. ( Site 0516) Magdeburg Sachsen-Anhalt
Germany Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0502) Tuebingen Baden-Wurttemberg
Hungary Bajcsy Zsilinszki Korhaz es Rendelointezet ( Site 1001) Budapest
Hungary Debreceni Egyetem Klinikai Kozpont ( Site 1006) Debrecen
Hungary Petz Aladar Megyei Oktato Korhaz ( Site 1012) Gyor
Hungary Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 1007) Kaposvar
Hungary Pecsi Tudomanyegyetem AOK ( Site 1009) Pecs Baranya
Hungary SZTE Szent-Gyorgyi Albert Klinikai Kozpont ( Site 1010) Szeged Csongrad
Hungary Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1002) Szolnok Jasz-Nagykun-Szolnok
Ireland Cork University Hospital ( Site 0722) Cork
Ireland Tallaght University Hospital ( Site 0710) Dublin
Ireland University Hospital Waterford ( Site 0723) Waterford
Israel Ha Emek Medical Center ( Site 0808) Afula
Israel Soroka Medical Center ( Site 0806) Beer Sheva
Israel Rambam Health Care Campus-Oncology Division ( Site 0802) Haifa
Israel Hadassah Ein Kerem Medical Center ( Site 0810) Jerusalem
Israel Shaare Zedek Medical Center ( Site 0809) Jerusalem
Israel Meir Medical Center ( Site 0803) Kfar Saba
Israel Rabin Medical Center ( Site 0804) Petach Tikva
Israel Sheba Medical Center ( Site 0801) Ramat Gan
Israel Sourasky Medical Center ( Site 0807) Tel Aviv
Israel Yitzhak Shamir Medical Center ( Site 0805) Zerifin
Italy A.O.U. Policlinico Vittorio Emanuele - Presidio Gaspare Rodolico ( Site 0559) Catania
Italy Istituto Nazionale Studio e Cura dei Tumori ( Site 0551) Milano
Italy Policlinico di Modena ( Site 0553) Modena Emilia-Romagna
Italy Istituto Nazionale Per Lo Studio E La Cura Dei Tumori ( Site 0552) Napoli
Italy Fondazione Salvatore Maugeri IRCCS. ( Site 0554) Pavia
Italy Azienda Ospedaliera San Camillo Forlanini ( Site 0560) Roma
Italy Policlinico Gemelli di Roma ( Site 0558) Roma Abruzzo
Italy Azienda Ospedaliera Santa Maria Terni ( Site 0557) Terni
Japan Chiba Cancer Center ( Site 1506) Chiba
Japan Harasanshin Hospital ( Site 1515) Fukuoka
Japan Saitama Medical University International Medical Center ( Site 1505) Hidaka Saitama
Japan Hirosaki University Hospital ( Site 1502) Hirosaki Aomori
Japan Hiroshima City Hiroshima Citizens Hospital ( Site 1513) Hiroshima
Japan Nara Medical University Hospital ( Site 1510) Kashihara Nara
Japan National Cancer Center Hospital East ( Site 1504) Kashiwa Chiba
Japan Nagano Municipal Hospital ( Site 1516) Nagano
Japan Osaka Metropolitan University Hospital ( Site 1512) Osaka
Japan Sapporo Medical University Hospital ( Site 1501) Sapporo Hokkaido
Japan Tokushima University Hospital ( Site 1514) Tokushima
Japan Tokyo Medical and Dental University Hospital ( Site 1517) Tokyo
Japan Ehime University Hospital ( Site 1508) Toon Ehime
Japan University of Tsukuba Hospital ( Site 1503) Tsukuba Ibaraki
Japan Yokosuka Kyosai Hospital ( Site 1509) Yokosuka Kanagawa
Korea, Republic of National Cancer Center ( Site 1354) Goyang-si Kyonggi-do
Korea, Republic of Seoul National University Bundang Hospital ( Site 1356) Seongnam-si Kyonggi-do
Korea, Republic of Asan Medical Center ( Site 1355) Seoul
Korea, Republic of Korea University Anam Hospital ( Site 1351) Seoul
Korea, Republic of Samsung Medical Center ( Site 1353) Seoul
Korea, Republic of Seoul National University Hospital ( Site 1352) Seoul
Mexico Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V. ( Site 0300) Aguascalientes
Mexico Centro Estatal de Cancerologia de Chihuahua ( Site 0253) Chihuahua
Mexico Centro de Urologia Avanzada del Noreste S.A. de C.V. ( Site 0254) Monterrey Nuevo Leon
Mexico Instituto Nacional de Cancerologia ( Site 0256) Tlalpan
Poland Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 1060) Bielsko-Biala Slaskie
Poland Centrum Onkologii im.prof. F. Lukaszczyka w Bydgoszczy ( Site 1068) Bydgoszcz Kujawsko-pomorskie
Poland Europejskie Centrum Zdrowia Otwock ( Site 1057) Otwock Mazowieckie
Poland Luxmed Onkologia sp. z o. o. ( Site 1051) Warszawa Mazowieckie
Poland Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 1062) Wroclaw Dolnoslaskie
Russian Federation Ivanovo Regional Oncology Dispensary ( Site 0852) Ivanovo Ivanovskaya Oblast
Russian Federation Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0861) Krasnoyarsk Krasnoyarskiy Kray
Russian Federation Kursk Regional Clinical Oncology Dispensary ( Site 0854) Kursk Kurskaya Oblast
Russian Federation Central Clinical Hospital with outpatient Clinic ( Site 0856) Moscow Moskva
Russian Federation FSBI ""United Hospital with Polyclinic"" of the Administrative Department of the President of the Ru Moscow Moskva
Russian Federation Bayandin Murmansk Regional Clinical Hospital ( Site 0859) Murmansk Murmanskaya Oblast
Russian Federation Volga District Medical Center Federal Medical and Biological Agency ( Site 0857) Nizhny Novgorod Nizhegorodskaya Oblast
Russian Federation Omsk Clinical Oncology Dispensary ( Site 0865) Omsk Omskaya Oblast
Russian Federation Leningrad Regional Oncology Center ( Site 0868) Saint Petersburg Sankt-Peterburg
Russian Federation Saratov State Medical University n.a. V.I.Razumovskiy ( Site 0866) Saratov Saratovskaya Oblast
Russian Federation Clinical Hospital Saint Luka ( Site 0867) St. Petersburg Sankt-Peterburg
Russian Federation Clinic of Bashkortostan State Medical University ( Site 0869) Ufa Baskortostan, Respublika
Spain Hospital del Mar ( Site 0653) Barcelona
Spain Hospital San Pedro de Alcantara ( Site 0654) Caceres Extremadura
Spain H. de Gerona Dr. Josep Trueta ( Site 0651) Girona Gerona
Spain Hospital Universitario La Paz ( Site 0661) Madrid
Spain Hospital Universitario Ramon y Cajal ( Site 0660) Madrid Madrid, Comunidad De
Spain Hospital Universitario San Carlos ( Site 0663) Madrid
Spain Hospital Universitario Quiron Madrid ( Site 0657) Pozuelo de Alarcon Madrid, Comunidad De
Spain Hospital Nuestra Sra. de Valme ( Site 0658) Sevilla
Spain Instituto Valenciano de Oncologia - IVO ( Site 0662) Valencia Valenciana, Comunitat
Sweden Laenssjukhuset Ryhov ( Site 1205) Jonkoping Jonkopings Lan
Sweden Cancercentrum ( Site 1204) Umea Vasterbottens Lan
Sweden Akademiska Sjukhuset ( Site 1201) Uppsala Uppsala Lan
Thailand Faculty of Medicine Siriraj Hospital ( Site 1452) Bangkok Krung Thep Maha Nakhon
Thailand Ramathibodi Hospital. ( Site 1451) Bangkok Krung Thep Maha Nakhon
Thailand Maharaj Nakorn Chiangmai Hospital ( Site 1453) Chiang Mai
Thailand Srinagarind Hospital ( Site 1454) Khon Kaen
Turkey Hacettepe Universitesi Tip Fakultesi ( Site 0911) Ankara
Turkey Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0910) Istanbul
Turkey TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 0906) Istanbul
Turkey Universitesi Pendik Egitim ve Arastirma Hastanesi ( Site 0901) Istanbul
Turkey Necmettin Erbakan Universitesi Meram Tip Fakultesi Hastanesi ( Site 0909) Konya
Turkey Sakarya Universitesi Tip Fakultesi ( Site 0913) Sakarya
Turkey Karadeniz Teknik Universitesi Tip Fakultesi Farabi Hastanesi ( Site 0904) Trabzon
Ukraine Cherkasy Regional Oncology Dispensary ( Site 0959) Cherkasy Cherkaska Oblast
Ukraine Dnipropetrovsk City Multidiscipline Clinical Hosp. 4 of DRC ( Site 0951) Dnipro Dnipropetrovska Oblast
Ukraine Regional Oncological Hospital ( Site 0956) Dnipro Dnipropetrovska Oblast
Ukraine MI Dnipr Regional Clinical Hospital named after I.I. Mechnikov ( Site 0963) Dnipropetrovsk Dnipropetrovska Oblast
Ukraine CNPE "Regional Center of Oncology" ( Site 0958) Kharkiv Kharkivska Oblast
Ukraine Reg. Clinical Center of Urology and Nephrology n.a. V. I. Shapoval ( Site 0969) Kharkiv Kharkivska Oblast
Ukraine Kyiv City Clinical Oncology Center ( Site 0960) Kyiv
Ukraine National Cancer Institute of the MoH of Ukraine ( Site 0962) Kyiv Kyivska Oblast
Ukraine Lviv Regional Clinical Hospital ( Site 0955) Lviv Lvivska Oblast
Ukraine Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 0967) Lviv Lvivska Oblast
United Kingdom Aberdeen Royal Infirmary ( Site 0708) Aberdeen Aberdeen City
United Kingdom Kent and Canterbury Hospital ( Site 0709) Canterbury England
United Kingdom Imperial College Healthcare NHS Trust ( Site 0721) London London, City Of
United Kingdom The Royal Marsden Foundation Trust ( Site 0702) London London, City Of
United Kingdom Norfolk & Norwich University Hospital NHS Foundation Trust ( Site 0725) Norwich Norfolk
United Kingdom Lister Hospital ( Site 0715) Stevenage Hertfordshire
United Kingdom Torbay Hospital ( Site 0704) Torquay Devon
United Kingdom Royal Cornwall Hospital ( Site 0703) Truro
United States UNM Comprehensive Cancer Center-Clinical Research Office ( Site 0045) Albuquerque New Mexico
United States Charleston Area Medical Center ( Site 0023) Charles Town West Virginia
United States University Hospitals Cleveland Medical Center ( Site 0038) Cleveland Ohio
United States Henry Ford Hospital ( Site 0039) Detroit Michigan
United States Inova Schar Cancer Institute ( Site 0007) Fairfax Virginia
United States Parkview Cancer Institute ( Site 0077) Fort Wayne Indiana
United States MD Anderson Cancer Center ( Site 0063) Houston Texas
United States Indiana University Melvin and Bren Simon Cancer Center ( Site 0004) Indianapolis Indiana
United States Scripps MD Anderson ( Site 0010) La Jolla California
United States Morristown Medical Center ( Site 0015) Morristown New Jersey
United States Ochsner Medical Center ( Site 0049) New Orleans Louisiana
United States New York University Perlmutter Cancer Center ( Site 0008) New York New York
United States AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 0005) Orlando Florida
United States Allegheny General Hospital ( Site 0048) Pittsburgh Pennsylvania
United States Portland VA Medical Center ( Site 0084) Portland Oregon
United States Northwest Medical Specialties, PLLC ( Site 0061) Puyallup Washington
United States Mercy Hospital Saint Louis ( Site 0064) Saint Louis Missouri
United States Providence Saint John's Health Center ( Site 0075) Santa Monica California
United States New England Cancer Specialists ( Site 0070) Scarborough Maine
United States Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0033) Seattle Washington
United States Central Texas Veterans Healthcare System ( Site 0057) Temple Texas
United States Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0021) Tulsa Oklahoma
United States Georgetown University Medical Center ( Site 0022) Washington District of Columbia
United States UMass Memorial Medical Center ( Site 0051) Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  Canada,  Denmark,  France,  Germany,  Hungary,  Ireland,  Israel,  Italy,  Japan,  Korea, Republic of,  Mexico,  Poland,  Russian Federation,  Spain,  Sweden,  Thailand,  Turkey,  Ukraine,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Event-Free Survival (EFS) EFS is defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes RC surgery; failure to undergo RC surgery in participants with residual disease and any radiographical disease present; gross residual disease left behind at the time of surgery; local or distant recurrence based on investigator assessments and/or biopsy, or death due to any cause. Up to approximately 60 months
Secondary Pathologic Complete Response (pCR) Rate pCR rate is defined as the percentage of participants having pCR. pCR is defined as absence of viable tumor (pT0N0) in examined tissue from RC and PLND, as assessed by blinded independent central review (BICR). Up to approximately 72 months
Secondary Overall Survival (OS) Overall survival is defined as the time from randomization to death due to any cause. Up to approximately 72 months
Secondary Disease-Free Survival (DFS) DFS is defined as the time from post-surgery baseline scan until the first occurrence of either local or distant recurrence as assessed by investigator by CT or MRI and/or computerized tomography (CT) or magnetic resonance imaging (MRI) and or biopsy or death from any cause. From approximately 20 weeks up to approximately 72 months
Secondary Pathologic Downstaging (pDS) Rate pDS rate is defined as the percentage of participants having pDS. pDS is defined as participants with a tumor classification of Up to approximately 72 months
Secondary Number of Participants Who Experienced an Adverse Event (AE) An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Up to approximately 72 months
Secondary Number of Participants Who Discontinued Study Treatment Due to an AE An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Up to approximately 12 months
Secondary Number of Participants Who Experienced Perioperative Complications An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Up to approximately 12 months
Secondary Change in Patient-Reported Outcomes from Baseline in Total Score of Functional Assessment of Cancer Therapy - General (FACT-G) The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0 to 4, with higher scores indicating higher HRQoL. The total score can range from 0 to 108. Baseline, Up to approximately 72 months
Secondary Change in Patient-Reported Outcomes from Baseline in Total Score of FACT-Bladder- (FACT-BI-Cys) Total Score of FACT BI-Cys is the sum of FACT-G total score and FACT-Bl-Cys score. FACT-Bl-Cys contains 17 items on the bowel, bladder, and sexual symptoms following cystectomy. The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0 to 4, with higher scores indicating higher HRQoL. The total score of FACT-Bl-Cys can range from 0 to 168. Baseline, Up to approximately 72 months
Secondary Change in Patient-Reported Outcomes from Baseline in FACT-BI-Cys-Trial Outcome Index (TOI) FACT-Bl-Cys Trial Outcome Index (TOI) is the sum of FACT-G PWB score, FWB score, and FACT-Bl-Cys score. FACT-Bl-Cys contains 17 items on the bowel, bladder, and sexual symptoms following cystectomy. The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0 to 4, with higher scores indicating higher HRQoL. The total score of FACT-Bl-Cys TOI can range from 0 to 116. Baseline, Up to approximately 72 months
Secondary Change in Patient-Reported Outcomes from Baseline in EuroQol Five-Dimensional Questionnaire (EQ-5D-5L) Visual Analog Score (VAS) The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. In the EQ-5D-5L VAS, the participant rates his or her general state of health at the time of the assessment on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. Baseline, Up to approximately 72 months
Secondary Time to Deterioration (TTD) in the Total Score of FACT-G The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0-4, with higher scores indicating higher HRQoL. TTD is defined as the time from baseline to the first onset of patient-reported outcomes (PRO) deterioration. For the FACT-G questionnaire, deteriorations are defined as a decrease of 7 points or more (out of 108) from baseline in total score. Up to approximately 72 months
Secondary TTD in EQ-5D-5L VAS The EQ-5D-5L is a standardized instrument for use as a measure of health outcome and includes 5 health state dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In the EQ-5D-5L VAS, the participant rates his or her general state of health at the time of the assessment on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. TTD is defined as the time from baseline to the first onset of PRO deterioration. For the EQ 5D-5L, deterioration is defined as a decrease of 7 points or more from baseline in the VAS. Up to approximately 72 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06034015 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers Phase 1
Recruiting NCT04235764 - En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Completed NCT02371447 - VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04081246 - Transurethral Modified En Bloc Resection For Large Bladder Tumours. N/A
Recruiting NCT06059547 - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer Phase 2
Terminated NCT04779489 - Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer N/A
Not yet recruiting NCT04493489 - Propranolol Adjuvant Treatment of Bladder Cancer Phase 2
Completed NCT03520231 - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Phase 2
Recruiting NCT04537221 - Nordic Cystectomy Study III - Transfusion
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT01955408 - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment N/A
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05562791 - A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer Phase 1
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT02781428 - To Detect the Sensitivity of the UroMark Assay
Recruiting NCT04738630 - Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Phase 2
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03978624 - Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Phase 2
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A